JANX

Janux is a pre-commercial oncology/autoimmune biotech whose entire $919M market cap rests on early-stage clinical assets — JANX007 (PSMA TRACTr in mCRPC, Phase 1), JANX008 (EGFR TRACTr, Phase 1), and the just-initiated JANX011 (CD19-ARM in healthy volunteers). The company explicitly states it has 'never generated any revenue from product sales' and the $10.0M FY2025 'revenue' is collaboration-related, not commercial — making the 91.9x P/S multiple meaningless as a valuation anchor. With operating margin of -1576.7% and net loss widening 64.7% YoY to -$114M, this is a binary clinical-readout story, not a fundamentals story.

The balance sheet is the immediate problem. Cash & equivalents fell 87.8% YoY to just $52.3M, while operating cash burn accelerated 87.7% to -$82.2M and R&D spend jumped 84.1% to $126M. At the current burn rate, $52M of cash funds roughly 7-8 months of operations — though the $976M current-assets line implies substantial marketable securities beyond pure cash that extend runway materially. Even so, the trajectory is unambiguous: burn is accelerating into expanding Phase 1 programs, the accumulated deficit ballooned 47.8% to -$351M, and dilution is already underway (shares +2.9% YoY) with more near-certain given the company lists 'issuance of common stock and pre-funded common stock warrants in public and/or underwritten offerings' as a core funding mechanism.